Animal StudyPubMed ID: 16822960·2006

Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse

Alba M, Fintini D, Bowers CY, et al.

American Journal of Physiology - Endocrinology and Metabolism, 2006

Key finding

CJC-1295 normalized body weight, body length, and organ weights in GHRH knockout mice, demonstrating full GHRH replacement capability.

Summary

Animal study demonstrating once-daily CJC-1295 completely normalized growth in GHRH-deficient mice, proving it can substitute for endogenous GHRH signaling.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

CJC-1295L3

A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.

More research on CJC-1295

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

Growth Hormone & IGF Research · 2008 · Human Pilot

CJC-1295 Effects on Sleep Quality and Slow-Wave Sleep

Sleep Medicine · 2008 · Human Pilot

Pharmacogenomics of CJC-1295: Individual Variation in GH Response

Journal of Clinical Endocrinology and Metabolism · 2008 · Human Pilot

CJC-1295 Improves Body Composition in Obese Adults

Journal of Clinical Endocrinology and Metabolism · 2007 · Human Pilot

CJC-1295 DAC Enhances Immune Function Through GH Signaling

Journal of Immunology · 2007 · Animal Study